Filter by:
Topic
Resource Type
Audience
Display Only
Showing 578 Results
NPC Shares Input on CMS’ Data Collection Requirements
NPC comments offer input on CMS' approach to data collection that would inform the agency's implementation of provisions within the Inflation Reduction Act that enable government price-setting for…
Medicaid Best Price Reforms Can Encourage Innovative Payment Arrangements for Chronic Therapies
This NPC study extends previous work analyzing reforms to CMS’ Medicaid Best Price reporting rules to encourage the uptake of value-based purchasing agreements for chronic disease treatments.
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Day serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies do…
In 2023, Decision Makers Should Dig into Data About Our Drug Pricing System
In Chain Drug Review, NPC's John O'Brien discusses how 2023 brings renewed imperative to root health policy decisions in evidence.
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
ICER Misses…Again
The latest Unsupported Price Increase Report from ICER lacks balance, uses flawed methods and may harm patients.
Skyrocketing Deductibles Should Be a Focus of Open-Enrollment Season
The dizzyingly complex process of shopping for health insurance can obscure some of the most important factors in making a choice.
After 30 years of 340B, it's time for data and an honest conversation
In a commentary published in STAT, NPC's John M. O’Brien outlines why transparency is essential to assessing the true impact of 340B.
Good Health Policy Requires High-Quality Evidence
In health policy debates, honest, realistic and evidence-based discussions are foundational.
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
The Impact of Price Regulation on Innovation: What the Research Shows
Potential drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
Predictors of Adherence to Oral Anticancer Medications: The Impact of Out-of-Pocket Costs
Biopharmaceutical innovation has led to an increase in the availability of oral anticancer medications (OAMs), but research shows that almost half of patients on OAMs do not take their medications as…
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Health Policy Fellow to Professor: Growth, Overcoming Challenges and the Road to Success
After two years as NPC's health policy fellow, Dr. Salama Freed takes a moment to reflect as we celebrate the next step in her career journey.
Bringing the Patient Voice Into Benefit Design
Diverse populations have diverse needs, and that's why NPC Chairman Steven Romano says benefit design and coverage policies should start with the patient in mind.
Commentary: "New York Times Piece on Drug Market Ignores the Data (and Reality)"
NPC's President and CEO John M. O'Brien addresses research using politically expedient shortcuts and the consequences on policy...and patients.